EUVIMEDEUVIMED entdecken
Crossref

Brigatinib-based targeted drug conjugates afford selective and potent anti-tumor efficacy in the treatment of pancreatic ductal adenocarcinoma

Heng Zhang, Wanxiang Yang, Xiao Ge, Gang Xu, Shaohua Gou

Bioorganic Chemistry · 2026-09 · 180 · 110247

DOI: 10.1016/j.bioorg.2026.110247 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic Chemistry, 2026-09. Verfasst von Heng Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, PR China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Pyrimidines. Die Arbeit nennt 36 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal human malignancies, as existing therapies lack sufficient tumor selectivity and offer dose-limiting systemic toxicity. Herein report is the design, synthesis, and biological evaluation of five novel EGFR-targeted drug conjugates (TDCs) upon our TDC strategy, which employs Brigatinib as the targeting moiety linked to various cytotoxic payloads. Molecular docking-guided conjugation maintained EGFR binding affinity across all TDCs (IC50 = 0.14-0.24 nM), and the representative compound BG2 exhibited potent antiproliferative activity against PANC-1 cells (IC50 = 0.68 μM) with a high selectivity index relative to normal cells. Further investigations revealed a diverse antitumor profile, mainly including inhibition of the EGFR/AKT pathway and induction of DNA double-strand breaks. In a PANC-1 xenograft model, BG2 achieved 67.79% tumor growth inhibition while preserving organ histology and maintaining stable body weight. These findings highlight the potential of the Brigatinib-based TDC platform as a precision therapeutic strategy for PDAC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsPancreatic NeoplasmsCarcinoma, Pancreatic DuctalPyrimidinesOrganophosphorus CompoundsProtein Kinase InhibitorsHumansCell ProliferationAnimalsDrug Screening Assays, AntitumorStructure-Activity RelationshipMolecular StructureMiceDose-Response Relationship, DrugCell Line, TumorErbB ReceptorsMolecular Docking Simulation

Stichwörter der Autor:innen

BrigatinibCamptothecinEGFR-targetedPancreatic ductal adenocarcinomaTargeted drug conjugate

Substanzen

Antineoplastic AgentsbrigatinibPyrimidinesOrganophosphorus CompoundsProtein Kinase InhibitorsErbB Receptors

Autor:innen und Institutionen

  • Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, PR China.
  • Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, PR China. Electronic address: xugang@seu.edu.cn.
  • Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, PR China. Electronic address: sgou@seu.edu.cn.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhang, H., Yang, W., Ge, X., Xu, G., & Gou, S. (2026). Brigatinib-based targeted drug conjugates afford selective and potent anti-tumor efficacy in the treatment of pancreatic ductal adenocarcinoma. Bioorganic Chemistry, 180, 110247. https://doi.org/10.1016/j.bioorg.2026.110247

Vancouver

Zhang H, Yang W, Ge X, Xu G, Gou S. Brigatinib-based targeted drug conjugates afford selective and potent anti-tumor efficacy in the treatment of pancreatic ductal adenocarcinoma. Bioorganic Chemistry. 2026;180:110247. doi:10.1016/j.bioorg.2026.110247

BibTeX
@article{Zhang2026,
  author = {Zhang, Heng and Yang, Wanxiang and Ge, Xiao and Xu, Gang and Gou, Shaohua},
  title = {Brigatinib-based targeted drug conjugates afford selective and potent anti-tumor efficacy in the treatment of pancreatic ductal adenocarcinoma},
  journal = {Bioorganic Chemistry},
  year = {2026},
  volume = {180},
  pages = {110247},
  doi = {10.1016/j.bioorg.2026.110247}
}
Kostenlos starten →